Figure 14.
(a) Structures of the components of theranostic dendrimersomes: JD 3,5-C12-EG-(OH)4, the GdDOTAGA(C18)2 complex (MRI contrast agent incorporated in the membrane bilayer) and the antitumour drug prednisolone phosphate (PLP); (b) Representative in vivo MR image showing the tumor after injection of dually-loaded DSs; (c) Time course of the tumour growth expressed as the percentage volume increase with respect to the initial tumor volume calculated at time 0 after the systemic administration of the control single-loaded DSs (Gd-DS, white circles), dual-loaded dendrimersomes (PLP-Gd-DS, black squares) or liposomes (PLP-Gd-Lipo, gray circles). Copyright Elsevier, reprinted from Journal of Controlled Release 2017 [81].